Prosecution Insights
Last updated: May 04, 2026
Application No. 18/255,468

SURFACE TREATMENTS UTILIZING IMMOBILIZED ANTIMICROBIAL PEPTIDE MIMICS

Non-Final OA §102§103
Filed
Jun 01, 2023
Priority
Dec 02, 2020 — provisional 63/120,686 +1 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Maxwell Biosciences Inc.
OA Round
2 (Non-Final)
66%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
872 granted / 1320 resolved
+6.1% vs TC avg
Strong +16% interview lift
Without
With
+16.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
51 currently pending
Career history
1371
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
44.3%
+4.3% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
14.4%
-25.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1320 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 12/10/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 102 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim 65-69, 71, 72, 74 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Messersmith (US 20100028719). Messersmith Teaches non-natural mimics of antimicrobial peptides, such as poly-N-substituted glycine (¶¶ 6 and 8) attached to TiO2 substrates via polymer, such as PEG, backfilling to form polymer brushes (¶ 44). Further teaches a brush like structure is expected when 2kDa PEG densities of 0.9 chains per nm2 are achieved, which suggests about 1nm between chains (¶ 55). The peptoids show activity against E. coli (¶¶ 28 and 31). With regards to claim 67, he working embodiments include the use of PEG-2000 (¶ 39, Fig 11). With regards to claim 68, glass substrates were also used (¶ 58). With regards to claim 69, about 2nm can be construed to be 1 nm. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 65-74 are rejected under 35 U.S.C. 103 as being unpatentable over Messersmith (US 20100028719). Messersmith further teaches varying the density of the polymer (paragraph 55), therefore as a matter of optimizing the brush like structure, the density would be varied, causing variation in the spacing, form 3-20 nm. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri (9am-6pm + mid-day flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jun 01, 2023
Application Filed
Sep 30, 2025
Non-Final Rejection — §102, §103
Dec 10, 2025
Response Filed
Apr 02, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12605345
Transdermal Drug Delivery System
2y 4m to grant Granted Apr 21, 2026
Patent 12589111
PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS
2y 10m to grant Granted Mar 31, 2026
Patent 12582745
ADHESIVE COMPOSITION FOR HARD TISSUE REPAIR
2y 9m to grant Granted Mar 24, 2026
Patent 12583865
Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration
2y 5m to grant Granted Mar 24, 2026
Patent 12582586
Oral Care Compositions
1y 9m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
66%
Grant Probability
82%
With Interview (+16.0%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1320 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month